CCP
ABUS icon

Corbin Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Corbin Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$2.23M Sell
682,487
-170,817
-20% -$628K 3.64% 5
2024
Q3 		$3.29M Hold
853,304
– – 4.15% 5
2024
Q2 		$2.2M Hold
853,304
– – 4.25% 8
2024
Q1 		$2.2M Buy
+853,304
New +$2.21M 3.72% 7

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Corbin Capital Partners's ABUS Position: Q4 2024 in Review

Corbin Capital Partners reduced its Arbutus Biopharma (ABUS) stake by 20% in Q4 2024, selling an estimated $628K and leaving 682,487 shares worth $2.23M. The position accounts for 3.64% of the portfolio, ranked #5.

Corbin Capital Partners first reported a position in ABUS in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.29M in Q3 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • Corbin Capital Partners held 682,487 shares of Arbutus Biopharma worth $2.23M as of Q4 2024.
  • Corbin Capital Partners sold 170,817 Arbutus Biopharma shares in Q4 2024, an estimated $628K.
  • Arbutus Biopharma made up 3.64% of Corbin Capital Partners's portfolio in Q4 2024, its #5 holding.
  • Corbin Capital Partners first reported a position in Arbutus Biopharma in Q1 2024 and has held it in 4 quarters since.
  • Corbin Capital Partners's Arbutus Biopharma position peaked at $3.29M in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on Corbin Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.